Search

Maria Jasin’s discoveries have led to concrete advances in patient care. The targeted medicines called PARP inhibitors, for example, are based on knowledge gained from her work.

… Saturday, January 1, 2022 By Matt Tontonoz Maria Jasin’s discoveries have led to concrete advances in patient care. The targeted medicines called PARP inhibitors, for example, are based on knowledge gained from her work. These drugs take advantage of the fact that tumors with a BRCA mutation are less

MSK researchers presented practice-changing advances in new treatment approaches for a range of cancer types at the 2025 ASCO Annual Meeting.Highlights included breakthroughs for patients with advanced gastric cancer, lung cancer, Lynch syndrome-related cancer and salivary gland cancer. Additionally, the first-ever CAR T cell trial for patients with light chain amyloidosis is showing promising results.

… Tuesday, June 3, 2025 Memorial Sloan Kettering Cancer Center (MSK) researchers presented practice-changing advances in new treatment approaches for a range of cancer types at the 2025 ASCO Annual Meeting held May 30 to June 3, 2025, in Chicago. Highlights included breakthroughs for patients with advanced

Dimiter Tassev, a member of Gerstner Sloan Kettering's inaugural class, has completed all his degree requirements and will receive his PhD in May.

… Tuesday, March 1, 2011 Dimiter Tassev, a member of Gerstner Sloan Kettering’s inaugural class, has completed all his degree requirements and will receive his PhD in May. Dr. Tassev did his thesis work in the laboratory of Nai-Kong Cheung . “My thesis project originally came about through my own personal

Foundation Medicine and Memorial Sloan Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.

… Thursday, May 2, 2013 Foundation Medicine and Memorial Sloan Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers. This effort will focus on co-development of a new Foundation Medicine molecular

Annually, Gerstner Sloan Kettering recognizes student research through fellowship awards with the Grayer Fellowships, the Catell Fellowship, the Olayan Fellowship, the Palestin Fellowship, and the Geoffrey Beene Graduate Student Fellowship.

… Friday, August 26, 2016 Gerstner Sloan Kettering student stipends are supported by a variety of sources including philanthropic fellowships. Annually, GSK awards fellowships to two third-year students and six second-year students based on academic excellence. Grayer Fellows Third-year students Jacob

New MSK research shows the Make-an-IMPACT program improves global access to genomic testing in pediatric cancer patients; helped develop an experimental antibody that shows promise against metastatic cancer; sheds light on the origins of ERG-driven prostate cancer; and finds Dupilumab is a successful agent to treat skin toxicities related to antibody-drug conjugates.

… Thursday, September 4, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) shows the Make-an-IMPACT program improves global access to genomic testing in pediatric cancer patients; helped develop an experimental antibody that shows promise against metastatic cancer; sheds light on the

MSK’s Kathryn Beal presents new findings on combining radiation with immunotherapy for brain cancer.

… Tuesday, September 27, 2016 Summary In this Q&A, MSK radiation oncologist Kathryn Beal discusses recent advances in treating brain cancer with a combination of radiation and immunotherapy. This week in Boston, radiation oncologists from around the world are attending the annual meeting of the American

Resection of all residual disease after salvage chemotherapy offers the best chance for a cure for patients with refractory or relapsed advanced testicular cancer, according to the results of our recent retrospective study.

… Friday, April 5, 2019 Resection of all residual disease after salvage chemotherapy offers the best chance for a cure for patients with refractory or relapsed advanced testicular cancer, according to the results of our recent retrospective study. The data, published in the journal Urology , underscores

Internationally recognized physician-scientist José Baselga has been named Physician-in-Chief of Memorial Hospital. He joins Memorial Sloan Kettering from Massachusetts General Hospital.

… Wednesday, September 5, 2012 Memorial Sloan Kettering Cancer Center announced today that José Baselga has been named Physician-in-Chief of Memorial Hospital . He will begin on January 1, 2013. Currently, Dr. Baselga is Chief of the Division of Hematology/Oncology at Massachusetts General Hospital (MGH

A study reveals unexpected insights into how cells prepare broken DNA strands to be rejoined, preventing mutations that can cause cancer.

… Friday, January 6, 2017 Summary Cells need to repair damaged DNA to prevent mutations that can lead to cancer. Though researchers know that broken DNA strands need to be processed in some way before they are rejoined, how this happens has been a mystery. A new study in yeast shows the early involvement